# Antineoplaston Therapy in Treating Patients With Multiple Myeloma

> **NCT00003511** · PHASE2 · TERMINATED · sponsor: **Burzynski Research Institute** · enrollment: 5 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Antineoplaston therapy (Atengenal + Astugenal)

## Key facts

- **NCT ID:** NCT00003511
- **Lead sponsor:** Burzynski Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1996-04-04
- **Primary completion:** 1999-10-21
- **Final completion:** 1999-10-21
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003511, "Antineoplaston Therapy in Treating Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00003511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*